Compare EVEX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | ORIC |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | 198 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 861.3M |
| IPO Year | N/A | 2020 |
| Metric | EVEX | ORIC |
|---|---|---|
| Price | $3.46 | $8.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $6.88 | ★ $19.73 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11,676.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $7.23 |
| 52 Week High | $7.70 | $14.93 |
| Indicator | EVEX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 65.89 | 39.95 |
| Support Level | $2.74 | $7.83 |
| Resistance Level | $4.44 | $11.22 |
| Average True Range (ATR) | 0.19 | 0.43 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 85.19 | 48.22 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.